408 research outputs found
Use of Lactobacillus farciminis to improve antioxidant status of Tuj lambs
The aim of this study was to investigate the effects of Lactobacillus farciminis on growth traits and antioxidant status in preweaning and postweaning Tuj lambs. Twenty lambs were divided into four groups, regardless of gender, with a mean live weight of 7.81 ± 0.50 kg. At the start of the experiment, the average age of the lambs was seven days. During the six-week preweaning period, control (C) lambs were fed with colostrum only, and Lactobacillus farciminis was given orally to the treated lambs at 1 g/day/lamb (L1), 2 g/day/lamb (L2) or 4 g/day/lamb (L3). The experiment continued for a total of 22 weeks. During the first six weeks, bodyweight (BW) increased significantly in L1 at the sixth week. Also during this period, bodyweight gain (BWG) in L2 at 2 - 3 weeks and in L3 at 5 - 6 weeks differed from C. In the subsequent period, BW and BWG were not affected by probiotic supplementation. The effects of probiotic supplementation on malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) were significant throughout the experiment, with the effect on glutathione (GSH) also being important in the first six weeks. Thus, Lactobacillus farciminis provided orally to Tuj breed lambs could be used to improve their antioxidant status without compromising growth
The impact of capital structure on the decision to outsource with long term contracts
This paper analyzes how capital structure affects the firms’ strategic choice between outsourcing with long term contracts and outsourcing to the spot market. When outsourcing to the spot market firms are exposed to price uncertainty, whereas a long term contract allows them to set in advance the outsourcing price. We show that, to the extent that leverage and uncertainty can lead to financial distress costs in bad states of nature, firms may use long term contracts as a risk management device to hedge input price uncertainty.N/
Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study
Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019.
Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019.
Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases.publishedVersio
The Relation Between the Surface Brightness and the Diameter for Galactic Supernova Remnants
In this work, we have constructed a relation between the surface brightness
() and diameter (D) of Galactic C- and S-type supernova remnants
(SNRs). In order to calibrate the -D dependence, we have carefully
examined some intrinsic (e.g. explosion energy) and extrinsic (e.g. density of
the ambient medium) properties of the remnants and, taking into account also
the distance values given in the literature, we have adopted distances for some
of the SNRs which have relatively more reliable distance values. These
calibrator SNRs are all C- and S-type SNRs, i.e. F-type SNRs (and S-type SNR
Cas A which has an exceptionally high surface brightness) are excluded. The
Sigma-D relation has 2 slopes with a turning point at D=36.5 pc: (at 1
GHz)=8.4 D
WmHzster (for
WmHzster and D36.5 pc) and (at 1
GHz)=2.7 10 D
WmHzster (for
WmHzster and D36.5 pc). We discussed the theoretical
basis for the -D dependence and particularly the reasons for the change
in slope of the relation were stated. Added to this, we have shown the
dependence between the radio luminosity and the diameter which seems to have a
slope close to zero up to about D=36.5 pc. We have also adopted distance and
diameter values for all of the observed Galactic SNRs by examining all the
available distance values presented in the literature together with the
distances found from our -D relation.Comment: 45 pages, 2 figures, accepted for publication in Astronomical and
Astrophysical Transaction
Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases
Deposition of immunoglobulin light chains is a result of clonal proliferation of monoclonal plasma cells that secrete free immunoglobulin light chains, also called Bence Jones proteins (Bence Jones proteins). These Bence Jones proteins are present in circulation in large amounts and excreted in urine in various light chain diseases such as light chain amyloidosis (AL), light chain deposition disease (LCDD) and multiple myeloma (MM). BJP from patients with AL, LCDD and MM were purified from their urine and studies were performed to determine their secondary structure, thermodynamic stability and aggregate formation kinetics. Our results show that LCDD and MM proteins have the lowest free energy of folding while all proteins show similar melting temperatures. Incubation of the BJP at their melting temperature produced morphologically different aggregates: amyloid fibrils from the AL proteins, amorphous aggregates from the LCDD proteins and large spherical species from the MM proteins. The aggregates formed under in vitro conditions suggested that the various proteins derived from patients with different light chain diseases might follow different aggregation pathways
New-onset diabetes after transplantation in tacrolimus-treated, living kidney transplantation: long-term impact and utility of the pre-transplant OGTT
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma
It is now clear that angiogenesis and angiogenesis factors are important in the pathogenesis of haematological malignancies. High pretreatment levels of serum basic fibroblast growth factor have been shown to be associated with poor prognosis in patients with non-Hodgkin's lymphoma. The aim of this study was to evaluate whether non-Hodgkin's lymphoma cells express basic fibroblast growth factor and/or its receptor (fibroblast growth factor receptor-1) and whether basic fibroblast growth factor expression correlates with basic fibroblast growth factor serum levels, intratumoral microvessel density, and patient outcome. We measured basic fibroblast growth factor by enzyme-linked immunosorbent assay in sera taken from 58 patients with non-Hodgkin's lymphoma before treatment and in 19 of them also after treatment. Pathological specimens at diagnosis were evaluated by immunohistochemistry staining using polyoclonal antibody against factor-VIII-related antigen, basic fibroblast growth factor and fibroblast growth factor receptor-1 to determine the expression of the microvessel count and basic fibroblast growth factor and fibroblast growth factor receptor-1. The lymphoma specimens demonstrated positive staining for basic fibroblast growth factor (in 23%) and fibroblast growth factor receptor-1 (in 58.5%). The patients who expressed basic fibroblast growth factor had a significantly worse progression-free and overall survival than those who did not (P=0.003 and P=0.03 respectively), while patients expressing fibroblast growth factor receptor-1 were less likely to achieve complete remission than those lacking the receptor (33% vs 65% , P=0.047). There was no correlation of basic fibroblast growth factor staining with either serum basic fibroblast growth factor levels or microvessel count. Basic fibroblast growth factor serum levels did not change significantly after treatment These results suggest that non-Hodgkin's lymphoma specimens express basic fibroblast growth factor and its receptor (fibroblast growth factor receptor-1) and this expression is associated with poor patient outcome
- …